You are here

  • Home
  • Archive
  • Volume 11, Issue 9
  • Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR

Authors

  • Emily Maria Ploeg Department of Surgery, Laboratory for Translational Surgical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands PubMed articlesGoogle scholar articles
  • Douwe Freerk Samplonius Department of Surgery, Laboratory for Translational Surgical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands PubMed articlesGoogle scholar articles
  • Xiao Xiong Department of Urology, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, ChinaFaculty of Medical Science and Integrated Chinese and Western Medicine Postdoctoral research station, Jinan University, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles
  • Xiurong Ke Department of Surgery, Laboratory for Translational Surgical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The NetherlandsAffiliated Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China PubMed articlesGoogle scholar articles
  • Mark Alexander Johannes Martinus Hendriks Department of Surgery, Laboratory for Translational Surgical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands PubMed articlesGoogle scholar articles
  • Isabel Britsch Department of Surgery, Laboratory for Translational Surgical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands PubMed articlesGoogle scholar articles
  • Anne Paulien van Wijngaarden Department of Surgery, Laboratory for Translational Surgical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands PubMed articlesGoogle scholar articles
  • Hao Zhang Department of General Surgery, Jinan University First Affiliated Hospital, Institute of Precision Cancer Medicine and Pathology, School of Medicine, Jinan University, Guangzhou, Guangdong, ChinaMinister of Education Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles
  • Wijnand Helfrich Department of Surgery, Laboratory for Translational Surgical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands PubMed articlesGoogle scholar articles

Citation

Ploeg EM, Samplonius DF, Xiong X, et al
Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR
Journal for ImmunoTherapy of Cancer 2023;11:e006837. doi: 10.1136/jitc-2023-006837
Online issue publication 
December 06, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.